93553-81-2

Basic information

• Product Name: 2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID
• Synonyms: 2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID;2-(3,4-dichlorophenyl)butanedioic acid
• CAS NO: 93553-81-2
• Molecular Formula: C₁₀H₈Cl₂O₄
• Molecular Weight: 263.07
• Mol File: 93553-81-2.mol

Chemical Properties

• Boiling Point: 370.9°C at 760 mmHg
• Flash Point: 178.1°C
• Appearance: /
• Density: 1.555g/cm³
• Vapor Pressure: 3.7E-06mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID(93553-81-2)
• EPA Substance Registry System: 2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID(93553-81-2)

Safety Data

• Hazardous Substances Data: 93553-81-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID is used as a key intermediate in the synthesis of various pharmaceutical agents. Its molecular structure and properties make it a valuable reagent for the development of new drugs with potential therapeutic applications.
Used in Agricultural Chemical Industry:
In the agricultural sector, 2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID is utilized as a building block in the production of herbicides and insecticides. Its unique structure contributes to the effectiveness of these chemicals in controlling pests and weeds, thereby enhancing crop protection and yield.
Used in Materials Science:
2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID has potential applications in the field of materials science, where its unique properties can be harnessed to develop new materials with specific characteristics, such as improved stability, reactivity, or selectivity.
Used as a Chiral Building Block:
Due to its chiral nature, 2-(3,4-DICHLORO-PHENYL)-SUCCINIC ACID can be employed as a chiral building block in the production of biologically active compounds. Its enantioselective synthesis allows for the creation of enantiomerically pure compounds, which are essential in various pharmaceutical and chemical applications.

InChI:InChI=1/C10H8Cl2O4/c11-7-2-1-5(3-8(7)12)6(10(15)16)4-9(13)14/h1-3,6H,4H2,(H,13,14)(H,15,16)

Upstream product

• 6287-38-3 3,4-dichlorobenzaldehyde 
• 55417-50-0 ethyl 2-cyano-3-(3,4-dichlorophenyl)-prop-2-enecarboxylate 
• 1412409-44-9 3,4-dichlorophenyl-α,β-dicyanoethyl propionate 

Downstream Products

• 81199-25-9 3-(3,4-dichlorophenyl)succinimide 
• 81199-31-7 1-Amino-3-(3,4-dichloro-phenyl)-pyrrolidine-2,5-dione 
• 93553-60-7 4-[3-(3,4-Dichloro-phenyl)-2,5-dioxo-pyrrolidin-1-yl]-benzenesulfonamide 
• 157904-53-5 5,6-dichloroindan-1-carboxylic acid 

Relevant articles and documents

Synthesis of 5, 6-dichloroindan-1-acids and their tetrazolyl derivatives as analgesic and anti-inflammatory agents

Indan derivatives, namely, 5-(5′,6′-dichloroindan-1′-yl)- tetrazole (12a) and 5-(5′,6′-dichloroindan-1′-yl)- methyltetrazole (12b), were synthesized conveniently from 5,6-dichloroindan-1- carboxylic acid (9a) and 5,6- dichloroindan-1-acetic acid (9b), respectively, as potential analgesic and anti-inflammatory agents. The analgesic and anti-inflammatory properties of 9a, 9b, 12a and 12b were evaluated by the acetic acid induced writhing in Swiss albino mice and the carrageenan-induced rat paw edema models, respectively. Compounds 9a and 12a exhibited significant analgesic activity with the doses of 50 and 100 mg/kg body weight, comparable to that of the positive controls, phenylbutazone, indomethacin and aminopyrine. The anti-inflammatory potencies of 9a and 12a were also comparable to that of the positive control, phenylbutazone. Compounds 9b and 12b showed analgesic and anti-inflammatory activities, but were weaker than that of compounds 9a and 12a.

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.